Evaluation of Stages, Treatment Protocols, and Outcomes of Colorectal Cancer among West Bank Patients
Conclusions: A high percentage of patients were diagnosed in advanced CRC stages. The treatment modes were adopted from general international guidelines; however, the cure rates were low, and mortality was high. More studies need to be undertaken to investigate the actual application of chemotherapy protocols, and survival would benefit from the involvement of clinical pharmacists in the chemotherapy protocol selection, dosing, frequency, and follow-up. The present study advocates for greater public awareness of CRC and attests to the merits of screening by primary care professionals, which can help to avoid this serious i...
Source: Clinical Colorectal Cancer - April 27, 2024 Category: Cancer & Oncology Authors: Ibrahim O Sawaid Abraham O Samson Rowa Al-Ramahi Source Type: research
Data-Driven Surveillance Protocol for Patients at Risk for Peritoneal Recurrence of Primary Colon Cancer: Surveillance for Peritoneal Carcinomatosis
This study assesses risk factors and time to recurrence of PC and implementation of a surveillance system. Patients with stage II-III colon adenocarcinoma undergoing curative colectomy between 2005-2022 were retrospectively reviewed at a single tertiary care institution. Patients were divided into three cohorts: no recurrence (NR), PC, and other types of recurrence (OTR). Baseline characteristics between cohorts were compared with univariate analysis. Overall survival and PC risk were assessed using multivariate analysis with Cox's proportional-hazard modelling. 412 patients were included; 78.4% had NR, 7.8% had PC, and 13...
Source: Clinical Colorectal Cancer - April 27, 2024 Category: Cancer & Oncology Authors: Meloria A Hoskins Adam Finkelstein Aisha Rashid Olivia Ziegler Marc M Mankarious Jorge V Benavides Colette R Pameijer Source Type: research
A Glimpse into the Role and Effectiveness of Splenectomy for Isolated Metachronous Spleen Metastasis of Colorectal Cancer Origin: Long-Term Survivals Can Be Achieved
Conclusions: Splenectomy is the optimal treatment for patients with isolated metachronous SM of CRC, with the laparoscopic approach being increasingly used and having the potential to become a standard of care. Encouraging long-term survival rates were reported in the context of a multidisciplinary approach. Younger ages are associated with worse survival. Perioperative chemotherapy in the context of a patient diagnosed with SM of CRC origin appears to be a reasonable option, although the present study failed to show any significant impact on long-term survival.PMID:38673636 | DOI:10.3390/jcm13082362 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 27, 2024 Category: Cancer & Oncology Authors: Beatrice Mihaela Tivadar Traian Dumitrascu Catalin Vasilescu Source Type: research
Do You Bleed? A 1-Year FOBT Case-Series Study
CONCLUSIONS: FOBT is inappropriately used in the hospital setting for GIB investigation. This study shows the inefficiency of FOBT to guide management and the high frequency of positive inpatient FOBT tests leading to unnecessary endoscopic investigation, longer hospitalizations, and delays in care. FOBT should be limited to the outpatient setting and be avoided while investigating GIB, anemia, etc. in the hospital.PMID:38668714 | DOI:10.1097/MCG.0000000000002016 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Spyridon Zouridis Daniel Sofia Osama Alshakhatreh Madeline Cleary Omar Daghstani Paul J Feustel Maheep Sangha Seth Richter Source Type: research
Follow-up Colonoscopy for Detection of Missed Colorectal Cancer after Diverticulitis
CONCLUSION: The risk of CRC cancer is low in most patients with diverticulitis. Patients with complicated diverticulitis are the exception. Our results suggest that colonoscopy to detect missed CRC should include diverticulitis patients with a complication and those not current with CRC screening.PMID:38670477 | DOI:10.1016/j.cgh.2024.03.036 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Walker D Redd Jennifer L Holub Hazel B Nichols Robert S Sandler Anne F Peery Source Type: research
SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis
CONCLUSIONS: Our findings revealed that SF3B3 promoted CRC progression and metastasis by regulating mTOR alternative splicing and SREBF1-FASN-mediated lipogenesis, providing strong evidence to support SF3B3 as a druggable target for CRC therapy.PMID:38671459 | DOI:10.1186/s13046-024-03053-4 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Tong Xu Xichuan Li Wennan Zhao Xue Wang Leixin Jin Zhiqiang Feng Huixiang Li Mingzhe Zhang Yiqing Tian Ge Hu Yuan Yue Xintong Dai Changliang Shan Weihua Zhang Chunze Zhang Youcai Zhang Source Type: research
Do You Bleed? A 1-Year FOBT Case-Series Study
CONCLUSIONS: FOBT is inappropriately used in the hospital setting for GIB investigation. This study shows the inefficiency of FOBT to guide management and the high frequency of positive inpatient FOBT tests leading to unnecessary endoscopic investigation, longer hospitalizations, and delays in care. FOBT should be limited to the outpatient setting and be avoided while investigating GIB, anemia, etc. in the hospital.PMID:38668714 | DOI:10.1097/MCG.0000000000002016 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Spyridon Zouridis Daniel Sofia Osama Alshakhatreh Madeline Cleary Omar Daghstani Paul J Feustel Maheep Sangha Seth Richter Source Type: research
Colorectal Cancer and Subsequent Diabetes Risk: A Population-based Cohort Study in Taiwan
CONCLUSION: Patients with CRC are associated with an elevated risk of diabetes mellitus, and long-term chemotherapy, particularly involving capecitabine, increases diabetes mellitus risk. Thus, monitoring blood glucose levels is crucial for patients with CRC, especially during extended chemotherapy.PMID:38661006 | DOI:10.1210/clinem/dgae257 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 25, 2024 Category: Cancer & Oncology Authors: Hsin-Yin Hsu Yih-Jong Chern Min-Shu Hsu Tzu-Lin Yeh Ming-Chieh Tsai Jing-Rong Jhuang Cheng-Tzu Hsieh Chun-Ju Chiang Wen-Chung Lee Lee-Ching Hwang Kuo-Liong Chien Source Type: research
miR-17-92a-1 cluster host gene: a key regulator in colorectal cancer development and progression
Clin Exp Med. 2024 Apr 25;24(1):85. doi: 10.1007/s10238-024-01331-1.ABSTRACTColorectal cancer (CRC), recognized among the five most prevalent malignancies and most deadly cancers, manifests multifactorial influences stemming from environmental exposures, dietary patterns, age, and genetic predisposition. Although substantial progress has been made in comprehending the etiology of CRC, the precise genetic components driving its pathogenesis remain incompletely elucidated. Within the expansive repertoire of non-coding RNAs, particular focus has centered on the miR-17-92a-1 cluster host gene (MIR17HG) and its associated miRNA...
Source: Clinical Colorectal Cancer - April 25, 2024 Category: Cancer & Oncology Authors: Amirhossein Mohajeri Khorasani Samane Mohammadi Alireza Raghibi Behzad Haj Mohammad Hassani Behina Bazghandi Pegah Mousavi Source Type: research
CircCOL1A1 promotes proliferation, migration, and invasion of colorectal cancer (CRC) cells and glutamine metabolism through GLS1 up-regulation by sponging miR-214-3p
CONCLUSION: These findings suggest that circCOL1A1 functions as an oncogenic molecule to promote CRC progression via miR-214-3p/GLS1 axis, hinting on the potential of circCOL1A1 as a therapeutic target for CRC.PMID:38662258 | DOI:10.1007/s00432-024-05736-z (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 25, 2024 Category: Cancer & Oncology Authors: Jia Liu Xianbo Zhang Meijian Yang Xianghong Zhang Source Type: research
Precision medicine in colorectal cancer: Leveraging multi-omics, spatial omics, and artificial intelligence
Clin Chim Acta. 2024 Apr 23:119686. doi: 10.1016/j.cca.2024.119686. Online ahead of print.ABSTRACTColorectal cancer (CRC) is a leading cause of cancer-related deaths. Recent advancements in genomic technologies and analytical approaches have revolutionized CRC research, enabling precision medicine. This review highlights the integration of multi-omics, spatial omics, and artificial intelligence (AI) in advancing precision medicine for CRC. Multi-omics approaches have uncovered molecular mechanisms driving CRC progression, while spatial omics have provided insights into the spatial heterogeneity of gene expression in CRC ti...
Source: Clinical Colorectal Cancer - April 25, 2024 Category: Cancer & Oncology Authors: Zishan Xu Wei Li Xiangyang Dong Yingying Chen Dan Zhang Jingnan Wang Lin Zhou Guoyang He Source Type: research
Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review
CONCLUSION: Evolving research on pembrolizumab allows a deeper clinical understanding, despite challenges as variable patient responses. Pembrolizumab has emerged as a pivotal breakthrough in cancer treatment, improving patient outcomes and safety.PMID:38658461 | DOI:10.1007/s12094-024-03491-8 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 24, 2024 Category: Cancer & Oncology Authors: V ítor Silva Cristiano Matos Source Type: research
Histopathological tumour microenvironment score independently predicts outcome in primary operable colorectal cancer
In conclusion, TMS represents a novel and clinically relevant method for subtyping CRC patients from a single H&E-stained tumour section.PMID:38650367 | PMC:PMC11035902 | DOI:10.1002/2056-4538.12374 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Phimmada Hatthakarnkul Kathryn Pennel Peter Alexander Hester van Wyk Antonia Roseweir Jitwadee Inthagard Jennifer Hay Ditte Andersen Noori Maka James Park Campbell Roxburgh Chanitra Thuwajit Donald McMillan Joanne Edwards Source Type: research
Human NLRC4 promotes cancer survival and is associated to type-I interferon signaling and immune infiltration
J Clin Invest. 2024 Apr 23:e166085. doi: 10.1172/JCI166085. Online ahead of print.ABSTRACTThe immune system can control cancer progression. However, even though some innate immune sensors of cellular stress are expressed intrinsically in epithelial cells, their potential role in cancer aggressiveness and subsequent overall survival in humans is mainly unknown. Here, we show that NLR family CARD Domain Containing 4 (NLRC4) is downregulated in epithelial tumor cells of colorectal cancer (CRC) patients by using spatial tissue imaging. Strikingly, only the loss of tumor NLRC4 but not stromal is associated with poor immune infi...
Source: Clinical Colorectal Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Charlotte Domblides Steven Crampton Hong Liu Juliet M Bartleson Annie Nguyen Claudia Champagne Emily E Landy Lindsey Spiker Christopher Proffitt Sunil Bhattarai Anissa P Grawe Matias Fuentealba Valenzuela Lydia Lartigue Isabelle Mahouche Jeremy Dupaul-Chi Source Type: research
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E
CONCLUSION: Per DLT criteria, binimetinib + pembrolizumab (cohort A) was tolerable, binimetinib + pembrolizumab + 5-fluorouracil, leucovorin, oxaliplatin (cohort C) did not qualify for binimetinib dose escalation to 45 mg, and binimetinib + pembrolizumab + 5-fluorouracil, leucovorin, irinotecan (cohort E) required binimetinib dose reduction from 45 to 30 mg. No new safety findings were observed across cohorts. There was no apparent additive efficacy when binimetinib + pembrolizumab was added to chemotherapy. Data did not support continued enrollment in cohorts C and E.PMID:38653648 | DOI:10.1016/j.clcc.2024.03.002 (Source:...
Source: Clinical Colorectal Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Eric X Chen Petr Kavan Mustapha Tehfe Jeremy S Kortmansky Michael B Sawyer E Gabriela Chiorean Christopher H Lieu Blase Polite Lucas Wong Marwan Fakih Kristen Spencer Jorge Chaves Chenxiang Li Pierre Leconte David Adelberg Richard Kim Source Type: research
